

tRNA-balanced expression of a eukaryal aminoacyl-tRNA synthetase by an mRNA-mediated pathway

Magali Frugier⁺, Michaël Ryckelynck & Richard Giegé

Département 'Machineries Traductionnelles', UPR 9002, Institut de Biologie Moléculaire et Cellulaire du CNRS, Strasbourg, France

Aminoacylation of transfer RNAs is a key step during translation. It is catalysed by the aminoacyl-tRNA synthetases (aaRSs) and requires the specific recognition of their cognate substrates, one or several tRNAs, ATP and the amino acid. Whereas the control of certain aaRS genes is well known in prokaryotes, little is known about the regulation of eukaryotic aaRS genes. Here, it is shown that expression of AspRS is regulated in yeast by a feedback mechanism that necessitates the binding of AspRS to its messenger RNA. This regulation leads to a synchronized expression of AspRS and tRNA^{Asp}. The correlation between AspRS expression and mRNA^{AspRS} and tRNA^{Asp} concentrations, as well as the presence of AspRS in the nucleus, suggests an original regulation mechanism. It is proposed that the surplus of AspRS, not sequestered by tRNA^{Asp}, is imported into the nucleus where it binds to mRNA^{AspRS} and thus inhibits its accumulation.

Keywords: aspartyl-tRNA synthetase; regulation; nucleus; tRNA; yeast

EMBO reports (2005) 6, 860–865. doi:10.1038/sj.embor.7400481

INTRODUCTION

For biological necessity, aminoacylation of transfer RNA has to be highly specific (Ibba *et al*, 2005). However, tRNA aminoacylation does not occur with absolute specificity. To reduce error levels, aminoacyl-tRNA synthetases have developed kinetic artifices that ensure best selection of their cognate tRNAs and amino acid, and destruction of the mischarged tRNAs (Ebel *et al*, 1973; Hendrickson & Schimmel, 2003). Because of the central role of tRNAs and aminoacyl-tRNA synthetases (aaRSs) in translation, adjustments of the rate of their synthesis can be advantageous to the cell. Such controls may prevent overexpression of aaRSs that would misacylate heterologous tRNAs, as recently shown in the case of yeast AspRS, where increased concentration of the enzyme generates aspartylated tRNA^{Asn} and tRNA^{Glu} *in vitro*

(Ryckelynck *et al*, 2003). *In vivo*, such errors would lead to the synthesis of erroneous proteins.

In prokaryotes, it is known that expression of aaRS genes can be transcriptionally or post-transcriptionally controlled (Ryckelynck *et al*, 2005). In yeast, it was shown that AspRS interacts with the 5' end of its own messenger RNA and lowers expression of a fused reporter protein (Frugier & Giegé, 2003). Interestingly, the affinity measured for the AspRS/mRNA^{AspRS} complex was found to be comparable with that determined for the AspRS/tRNA^{Asp} complex. Protein and mRNA variants allowed identification of the domains involved in this complex. In mRNA^{AspRS}, they encompass a sequence of 248 residues extending from nucleotide –38 in the 5' untranslated region (5'UTR) to nucleotide 210 in the coding sequence; in AspRS, it is the anticodon-binding domain and the amino-terminal extension (NTE) that contact the mRNA. This appendix, probably of helical architecture (Agou *et al*, 1995), protrudes from the anticodon-binding module of AspRS (Ruff *et al*, 1991) and contains an RNA-binding motif (₂₉XSKxxLKKxK₃₈) responsible for interaction with the anticodon branch of tRNA^{Asp} (Frugier *et al*, 2000). Even if this interaction is not essential for aspartylation, it increases the stability of the complex and the global efficiency of aminoacylation (Ryckelynck *et al*, 2003). On the basis of these observations and the data reported here, we propose a new mechanism for the regulation of AspRS expression in yeast (Fig 1). In short, the model implies the import of excess cytoplasmic AspRS into the nucleus, where it binds alternatively to the newly transcribed tRNA^{Asp} or to mRNA^{AspRS}, which leads to the inhibition of its own expression.

RESULTS AND DISCUSSION

The classical way to study expression regulation of a protein gene consists in increasing its copy number and then analysing the intracellular concentration of the biosynthesized protein. Thus, a yeast null strain (deleted of the endogenous AspRS gene) for AspRS was complemented with the AspRS gene cloned into a centromeric or a multicopy (2 μ) plasmid. In both cases, no stimulation in AspRS expression could be detected, which suggests that AspRS expression is regulated. This regulation may involve a third molecule that would control the expression mechanism. If so, an obvious candidate is tRNA^{Asp}, the cognate substrate of AspRS. To test this possibility, a wild-type yeast strain was transformed with a plasmid carrying the coding sequence for AspRS and two flanking

Département 'Machineries Traductionnelles', UPR 9002, Institut de Biologie Moléculaire et Cellulaire du CNRS, 15 rue René Descartes, 67084 Strasbourg Cedex, France

⁺Corresponding author. Tel: +33 3 88 41 70 59; Fax: +33 3 88 60 22 18; E-mail: m.frugier@ibmc.u-strasbg.fr

Received 22 April 2005; revised 9 June 2005; accepted 9 June 2005; published online 29 July 2005




Fig 1 | Model for yeast AspRS feedback regulation and potential effects of AspRS on the nuclear population of mRNA^{Asp}. The three-dimensional structure of one monomer of the AspRS core (Ruff *et al*, 1991) is given (in light brown) with the modelled amino-terminal extension (in blue; Frugier *et al*, 2000) appended to the anticodon-binding domain. The location of the RNA-binding domain in the second helix of the appendix (in magenta) and its binding with tRNA are indicated (Frugier *et al*, 2000). The steps that are potentially affected during the regulation process are indicated in red.

sequences large enough to include all the information necessary for an endogenous transcription of the gene. This strain was subsequently co-transformed with plasmids carrying one gene copy of tRNA^{Ile}, used as a control, or tRNA^{Asp}. As anticipated, the intracellular concentration of tRNA^{Asp} remained unchanged in the control experiment (Fig 2A, lane 1) and increased significantly (about fivefold) in the strain transformed with the plasmid carrying the tRNA^{Asp} gene (Fig 2A, lane 2). The variations in cellular tRNA^{Asp} concentration are accompanied by strong intensifications (about fivefold) in the mRNA^{AspRS} and AspRS expression patterns (Fig 2A, lanes 1,2). Indeed, expression of native AspRS is strongly enhanced when tRNA^{Asp} is overexpressed, whereas the internal mRNA and protein controls (mRNA^{β-actin} and G6PDH expression) remain constant. Thus, by coexpressing AspRS and its cognate tRNA^{Asp}, it is shown that AspRS translation is dependent on mRNA^{AspRS} concentration and correlates with the level of cellular tRNA^{Asp}. Because of the importance of the lysine-rich RNA-binding motif in AspRS NTE for binding its mRNA (Frugier & Giegé, 2003), an AspRS variant that lacked this motif was designed. With this mutant, variations in AspRS and mRNA^{AspRS} expression are no longer correlated to tRNA concentrations (Fig 2A, lanes 3,4). This is indicative of a feedback regulation that necessitates an intact RNA-binding motif that enables the formation of a complex between the synthetase and its mRNA.

AspRS NTE was also predicted to be a nuclear localization signal (NLS; Schimmel & Wang, 1999). To bring an experimental answer to this prediction, DNA sequences corresponding to AspRS constructs deleted in their NTE (native, Δ30, Δ50 and Δ70 AspRSs) were cloned in a centromeric plasmid and transformed in a yeast strain deleted of its endogenous AspRS (null strain). Nucleus purifications from these strains allowed us to explore the synthetase compartmentalization, without being misled by the high cytoplasmic AspRS concentration. Data clearly indicate that all AspRS forms are present in the nuclear fractions (Fig 3). This finding is one of the few examples of nuclear aaRS localization (Mucha, 2002), and suggests that AspRS nuclear import requires a mechanism other than the classical NLS process (Christophe *et al*, 2000). Furthermore, this result sheds new light on the mechanism that accounts for AspRS regulation. Indeed, significant differences in the concentrations of AspRS variants were detected in the nucleus, whereas their cytoplasmic counterparts did not show any differences. The wild-type and truncated Δ30 AspRSs, both of which contain the RNA-binding motif, are less concentrated in the nucleus than the two other variants that do not contain this motif (Fig 3). The nuclear accumulation of Δ50 and Δ70 AspRSs could be a consequence of a loss of control consecutive to the loss of binding properties towards their mRNA and also to their reduced affinity for tRNA^{Asp} in the cytoplasm. These data show that even




Fig 2 | Expression levels of protein and RNAs. (A) Analysis of wild-type and mutant AspRS and mRNA^{AspRS} expressions in yeast strains without (–) or with (+) plasmids encompassing an extra tRNA^{Asp} gene (in the (–) strains, the tRNA^{Asp} gene was replaced by a tRNA^{Ile} gene). Controls (c) correspond to nontransformed cells. (B) mRNA^{AspRS} and tRNA^{Asp} expression under the control of heterologous promoters. AspRS genes (wild type or mutated) were cloned under the control of the glyceraldehyde-3 phosphate dehydrogenase (GPD) promoter (strong constitutive promoter) or the Gal 1 promoter (strong inducible promoter) and the level of mRNA^{AspRS} expression was determined in the presence of different tRNA^{Asp} concentrations. No results were obtained with the mutated AspRS expressed under the GPD promoter, because the transformed yeast strains cannot grow properly. Quantitative data are given, representing mean values (about ±20%) of two independent experiments; values were calculated as a ratio of AspRS or mRNA^{AspRS} or tRNA^{Asp} with respect to controls and normalized towards the internal calibration controls (glucose 6-phosphate dehydrogenase (G6PDH), the mRNA encoding β-actin and 5S rRNA, respectively).




Fig 3 | Detection of AspRS in the nucleus. Western blots on nuclear and cytoplasmic fractions using antibodies against AspRS (present in both fractions), ValRS (only cytoplasmic) and RNA polymerase II (only nuclear).

when AspRS expression is no longer regulated, its concentration in the cytoplasm remains the same. Variations appear only in the nucleus, indicating that spare synthetase is segregated away from the translation site.

These results can be interpreted in two ways. (i) AspRS expression would be regulated by a translational mechanism that is consistent with other regulations mediated by RNA-binding proteins targeted to specific motifs in their own mRNA (McCarthy, 1998). The binding of AspRS to the 5'UTR of mRNA^{AspRS} as well as the dependence towards tRNA^{Asp} concentration seems

reminiscent of what occurs in the well-known *Escherichia coli* threonine system (Romby & Springer, 2003). Here, ThrRS binds specifically to its own mRNA operator and inhibits its translation by hindering ribosome binding. ThrRS acts as a translational repressor, and the resulting inhibition is abolished by the increased concentration of tRNA^{Thr}. (ii) Nevertheless, as mRNA^{AspRS} expression correlates directly with the profile of AspRS expression (Fig 2), it may also be that AspRS expression relies on a transcriptional control with the contribution of regulatory promoter elements (Kornberg, 1999) and/or mRNA turnover.

To check for the presence of binding sites for putative gene-specific transcriptional regulatory factors, the 5'UTR of mRNA^{AspRS} was fused directly downstream of two foreign promoters, namely the strong constitutive promoter of glyceraldehyde-3 phosphate dehydrogenase (GPD) and the strong inducible promoter Gal 1. Despite the reduced growth rate of the corresponding yeast transformants, the level of expression of wild-type mRNA^{AspRS} under the control of the GPD promoter is reduced when tRNA^{Asp} concentration is low and is stimulated when it increases (Fig 2B, left panels). This means that the controlled expression of AspRS does not involve any specific regulatory promoter element and that the messenger contains all the information necessary to regulate the synthetase level *in vivo*. One also observes that the same construct containing the mutated AspRS does not form viable yeast transformants. On the contrary, AspRS expressed under the Gal 1 promoter does not undergo its own regulation. This can be explained by the high activation of transcription following galactose induction (Fig 2B, right panels).

This feature was useful in the next experiments when testing the rate of mRNA^{AspRS} degradation.

At this point, it is tempting to propose that the mRNA^{AspRS}/AspRS complex is responsible for the inhibition of mRNA^{AspRS} stabilization. Indeed, post-transcriptional control of gene expression can also be achieved by controlling mRNA decay (Gingerich *et al*, 2004; Wilusz & Wilusz, 2004). For example, it has been shown in *E. coli* that an excess of ribosomal L2 protein directs its own mRNA to a degradative pathway (Presutti *et al*, 1991). However, to some extent, this regulation is similar to that of AspRS, as recognition of mRNA^{L2} by protein L2 is essential and requires a large region in the messenger (−21 to +339). Thus, the effect of AspRS binding capacity on the stability of mRNA^{AspRS} was tested in strains expressing wild-type or mutated AspRSs. Under galactose induction, transcription of both wild-type and mutated mRNAs is stimulated (Fig 4A). Even if the mutated mRNA^{AspRS} seems to accumulate slightly more rapidly than the wild-type mRNA, addition of glucose in the medium blocks the Gal 1-dependent transcription, and both mRNAs show the same stability (Fig 4B). The similar rates of decay indicate that

mRNA^{AspRS} turnover is not the consequence of an accelerated degradation by AspRS binding.

The above experimental evidence supports the existence of a new mechanism for the control of yeast AspRS (Fig 1) that differs from what is known in the aaRS field. One can presume that AspRS regulation is neither translational, as for *E. coli* ThrRS, nor linked to mRNA degradation, as for protein L2. However, the three systems share in common the fact that the crucial step in their regulation is the capacity of the protein to bind to its own mRNA. Here, the variations in mRNA^{AspRS} concentration and the presence of the synthetase in the nucleus are in favour of an early nuclear interaction, thus determining the future fate of the transcript from the very beginning. Although all mechanistic details are not deciphered, the mechanism is based on a series of robust evidences. Key features are the synchronized synthesis of AspRS and tRNA^{Asp}, the correlated synthesis of AspRS and mRNA^{AspRS}, the involvement of the NTE in the control mechanism and the nuclear localization of a fraction of the synthetase. Further, the dependence of AspRS control on tRNA^{Asp} concentration indicates that yeast maintains an adequate balance




Fig 4 | Accumulation and stability of mRNA^{AspRS}. (A) Northern blot analysis of mRNA^{AspRS} accumulation (45, 90, 135 and 180 min at 30 °C) and degradation (185, 190, 200, 240 and 300 min at 30 °C). The use of the galactose-inducible promoter allows one to overcome the regulation process of AspRS and accumulate enough mRNA^{AspRS} and measure its degradation rate. After 3 h, glucose was substituted for galactose in the medium (arrows) to stop mRNA transcription. (B) Graphical representation of the accumulation and degradation rates corresponding to both wild-type (grey) and mutated (black) mRNA^{AspRS}.

between the amounts of synthetase and its cognate tRNA. Rationalizing these facts leads to the following scenario for the regulation of yeast AspRS (Fig 1). When significant amounts of AspRS molecules are not sequestered by tRNA^{Asp} in the cytoplasm, the synthetase in excess is imported in the nucleus. There, it binds to the 5' end of its mRNA and thereby inhibits its own transcription. As a consequence, AspRS concentration decreases in the cytoplasm. In this model, part of yeast AspRS is imported in the nucleus, where both its substrates, namely the newly transcribed cognate tRNA^{Asp} and the coding mRNA^{AspRS}, are present. Thus, AspRS can either bind to the 5' end of its mRNA and inhibit its accumulation or aminoacylate the newly synthesized tRNA^{Asp} and further enhance its export to the cytoplasm (Azad *et al*, 2001; Steiner-Mosonyi & Mangroo, 2004). This nuclear localization also justifies the influence of tRNA^{Asp} concentration on AspRS expression, as the newly transcribed tRNA^{Asp} can compete directly with mRNA^{AspRS} and thus release the transcriptional inhibition. As AspRS undergoes its own regulation even when expressed under the control of a different transcriptional promoter, this model, in some aspects, resembles the activation of gene expression in human immunodeficiency virus-1, where the Tat viral protein acts as an unusual transcription factor. It recognizes a stem-loop RNA structure (TAR) present at the 5' end of the viral transcripts and this interaction promotes viral transcription by inducing chromatin modifications and by stimulating the recruitment of RNA polymerase II complexes (Marcello *et al*, 2001).

The interconnected control of both yeast AspRS and tRNA^{Asp} cellular concentrations would help to significantly reduce the risk of errors during translation. This control probably occurs as shown in Fig 1, in a model that accounts best for the reported experimental data. Its originality lies in a dual character, combining features acting at the post-transcriptional level, as interaction of AspRS with its own mRNA is essential, and at the transcriptional level, leading to the arrest of mRNA^{AspRS} transcription. At this stage of our study, we are aware that all mechanistic details of the regulation scenario are not deciphered, in particular what occurs in the nucleus and the putative participation of macromolecular partners recruited by AspRS when bound to mRNA^{AspRS}. Also, we cannot exclude other post-transcriptional events, such as the possible inhibition of mRNA export from the nucleus or of translation, that would help the cell to keep AspRS expression under a control that is as efficient and reactive as possible. Experiments are in progress to unravel the uncertainties and also to understand, at the molecular level, how AspRS recognizes its mRNA.

METHODS

Strains, plasmids and mutants. Construction of the AspRS-gene-disrupted YAL3 strain was described by Ador *et al* (1999). The amino-terminal-deleted AspRS genes (native, $\Delta 30$, $\Delta 50$ and $\Delta 70$) were cloned in the centromeric pRS314 (Trp⁺) and used to complement the YAL3 strain and study their cellular localization. YAL3 transformants were selected on a minimal medium supplemented with uracil, lysine, leucine and limiting concentrations of adenine (2 μ g/ml). After 72 h incubation at 30 °C, the Trp⁺ Sect⁺ colonies were isolated and screened for 5-fluoroorotic acid resistance.

For overproduction experiments, strain YBC 603 (*ade2::hisG his3 Δ 200 leu2 Δ 0 lys2 Δ 0 met15 Δ 0 trp1 Δ 63 ura3 Δ 0*) was

transformed with plasmid pFL45S (2 μ , Trp⁺) containing a 3.8 kb DNA fragment encoding AspRS and endogenous transcription promoter and terminator. AspRS was expressed under the control of the strong constitutive promoter of GPD on plasmid pRS426 (2 μ , Ura⁺) and of the strong inducible promoter Gal 1 on plasmid pRS425 (2 μ , Leu⁺). tRNA genes (tRNA^{Asp} and tRNA^{Ile}) were PCR amplified with their own promoter and terminator regions using yeast genomic DNA as template, and introduced into pRS426 or pRS425.

The lysine-rich RNA-binding motif in the N-terminal extension of AspRS was altered by introducing a +1 frameshift (insertion) at position 83 in the coding sequence of mRNA^{AspRS} and re-establishment of the reading frame (deletion) at position 147. Thus the wild-type sequence ₃₀SKKALKKLLQKEQEKQRKKE₄₈ was replaced by the mutated sequence ₃₀LVQEGLEEEAERARETEKE₄₈. **RNA analysis.** Yeast strains transformed with pRS425-Gal 1 containing the wild-type or the mutated AspRS genes were grown to an optical density (OD)_{600 nm} of 0.3–0.4 in 2% glucose media. The cultures were induced in the presence of 2% galactose and 0.1% glucose, and aliquots were analysed by northern blotting after 45, 90, 135 and 180 min. To stop induction, galactose was replaced with 4% glucose and samples were collected after 5, 10, 20, 60 and 120 min incubation at 30 °C. Other yeast strains were grown on amino-acid-supplemented minimal media for 15 h at 30 °C and 180 r.p.m. Cells were collected by centrifugation, washed in PBS and total RNA was extracted as described previously (Schmitt *et al*, 1990). After ethanol precipitation, 15 μ g (RNA stability) or 20 μ g of total cellular RNA was analysed by northern blots using the NorthernMax kit (Ambion, Austin, TX, USA) and ³²P-labelled probes prepared with the NonaPrimer kit (Quantum Appligene, France). Signal analysis and quantification were carried out on a Fuji Bioimager Bas2000 with Work Station Software (v1.1).

For tRNA detection, 15 μ g of total RNA was resolved on a 1-mm-thick 12% polyacrylamide gel/8M urea in Tris–borate–EDTA buffer, and transferred to a nylon membrane (Hybond-XL) and baked for 3 h at 80 °C using a gel dryer. Hybridization was performed for 12 h at 60 °C in 15 ml of Denhardt's solution, 5 \times SSPE (saline/sodium phosphate/EDTA) and 0.5% SDS, with probes against tRNA^{Asp}, tRNA^{Ile} and 5S RNA. Each probe corresponded to the 5'-end sequence of the given RNA and was 5'-end ³²P labelled.

Cell lysis and western blotting. Cells were collected, washed, quantified (OD_{600 nm}) and lysed in SDS loading buffer for 5 min at 90 °C. Equivalent amounts of crude extract (0.01 OD) were resolved on 12% polyacrylamide SDS gels, transferred to Immobilon-P transfer membranes (Millipore, Bedford, MA, USA) and probed with anti-AspRS antibody or a 1:5,000 dilution of anti-G6PDH antibody (Sigma, St Louis, MI, USA). Primary antibody was detected by a 1:5,000 dilution of horseradish peroxidase-conjugated goat anti-rabbit antibody (Amersham Biosciences, Buckinghamshire, UK).

Nucleus purification. Nucleus purifications were carried out according to Galy *et al* (2000). To obtain equivalent signals with both cytoplasmic and nuclear fractions, seven times more nuclear than cytoplasmic proteins (in equivalent number of cells) were loaded on the denaturing gel, blotted and detected using antibodies against AspRS, RNA polymerase II (α -subunit) or ValRS from yeast.

ACKNOWLEDGEMENTS

We thank M. Springer and C. Florentz for their critical reading and comments on the manuscript, G. Eriani and A. Lescure for their advice and discussion, P. Erbs and J. Boeke for yeast strains and M. Vigneron, G. Eriani and F. Fasiolo for antibodies. This work was supported by grants from the Centre National de la Recherche Scientifique (CNRS), Ministère de l'Éducation Nationale, de la Recherche et de la Technologie (MENRT) and Université Louis Pasteur.

REFERENCES

- Ador L, Camasses A, Erbs B, Cavarelli J, Moras D, Gangloff J, Eriani G (1999) Active site mapping of yeast aspartyl-tRNA synthetase by *in vivo* selection of enzyme mutations lethal for cell growth. *J Mol Biol* **288**: 231–242
- Agou F, Yang Y, Gesquière J-C, Waller J-P, Guittet E (1995) Polyanion-induced α -helical structure of a synthetic 23-residue peptide representing the lysine-rich segment of the N-terminal extension of yeast cytoplasmic aspartyl-tRNA synthetase. *Biochemistry* **34**: 569–576
- Azad AK, Stanford DR, Sarkar S, Hopper AK (2001) Role of the nuclear pools of aminoacyl-tRNA synthetases in tRNA nuclear export. *Mol Biol Cell* **12**: 1381–1392
- Christophe D, Christophe-Hobertus C, Pichon B (2000) Nuclear targeting of proteins: how many different signals? *Cell Signal* **12**: 337–341
- Ebel J-P, Giegé R, Bonnet J, Kern D, Bedford N, Bollack C, Fasiolo F, Gangloff J, Dirheimer G (1973) Factors determining the specificity of the tRNA aminoacylation reaction. *Biochimie* **55**: 547–557
- Frugier M, Giegé R (2003) Yeast aspartyl-tRNA synthetase binds specifically its own mRNA. *J Mol Biol* **331**: 375–383
- Frugier M, Moulinier L, Giegé R (2000) A domain in the N-terminal extension of class IIb eukaryotic aminoacyl-tRNA synthetases is important for tRNA binding. *EMBO J* **19**: 2371–2380
- Galy V *et al* (2000) Nuclear pore complexes in the organization of silent telomeric chromatin. *Nature* **403**: 108–112
- Gingerich TJ, Feige JJ, LaMarre J (2004) AU-rich elements and the control of gene expression through regulated mRNA stability. *Anim Health Res Rev* **5**: 49–63
- Hendrickson TL, Schimmel P (2003) Transfer RNA-dependent amino acid discrimination by aminoacyl-tRNA synthetases. In *Translation Mechanisms*, Lapointe J, Brakier-Gingras L (eds) pp 34–64. Georgetown, USA: Landes Bioscience
- Ibba M, Francklyn C, Cusack S (eds) (2005) *The Aminoacyl-tRNA Synthetases*. Georgetown, USA: Landes Bioscience
- Kornberg RD (1999) Eukaryotic transcriptional control. *Trends Cell Biol* **12**: 46–49
- Marcello A, Zoppe M, Giacca M (2001) Modes of transcriptional regulation by the HIV-1 Tat transactivator. *IUBMB Life* **51**: 175–181
- McCarthy EG (1998) Posttranscriptional control of gene expression in yeast. *Microbiol Mol Biol Rev* **62**: 1492–1553
- Mucha P (2002) Aminoacyl-tRNA synthetases and aminoacylation of tRNA in the nucleus. *Acta Biochim Pol* **49**: 1–10
- Presutti C, Ciafré SA, Bozzoni I (1991) The ribosomal protein-L2 in *Saccharomyces cerevisiae* controls the level of accumulation of its own messenger-RNA. *EMBO J* **10**: 2215–2221
- Romby P, Springer M (2003) Bacterial translational control at atomic resolution. *Trends Genet* **19**: 155–161
- Ruff M, Krishnaswamy S, Boeglin M, Poterzman A, Mitschler A, Podjarny A, Rees B, Thierry J-C, Moras D (1991) Class II aminoacyl transfer RNA synthetases: crystal structure of yeast aspartyl-tRNA synthetase complexed with tRNA^{Asp}. *Science* **252**: 1682–1689
- Ryckelynck M, Giegé R, Frugier M (2003) Yeast tRNA^{Asp} charging accuracy is threatened by the N-terminal extension of aspartyl-tRNA synthetase. *J Biol Chem* **278**: 9683–9690
- Ryckelynck M, Giegé R, Frugier M (2005) tRNAs and tRNA mimics as cornerstones of aminoacyl-tRNA synthetase regulations. *Biochimie* 11 May 2005; doi:10.1016/j.biochi.2005.02.014 [epub ahead of print]
- Schimmel P, Wang C-C (1999) Getting tRNA synthetases into the nucleus. *Trends Biochem Sci* **24**: 127–128
- Schmitt ME, Brown TA, Trumtower BL (1990) A rapid and simple method for preparation of RNA from *Saccharomyces cerevisiae*. *Nucleic Acids Res* **18**: 3091–3092
- Steiner-Mosonyi M, Mangroo D (2004) The nuclear tRNA aminoacylation-dependent pathway may be the principal route used to export tRNA from the nucleus in *Saccharomyces cerevisiae*. *Biochem J* **378**: 809–816
- Wilusz CJ, Wilusz J (2004) Bringing the role of mRNA decay in the control of gene expression into focus. *Trends Genet* **20**: 491–497